Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 34.57 Billion KRW | -34.86% |
| 2022 | 53.08 Billion KRW | -26.52% |
| 2021 | 72.24 Billion KRW | 140.56% |
| 2020 | 30.02 Billion KRW | -0.94% |
| 2019 | 30.31 Billion KRW | 236.85% |
| 2018 | 9 Billion KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| 2011 | - KRW | 0.0% |
| 2010 | - KRW | -100.0% |
| 2009 | 3 Billion KRW | 150.0% |
| 2008 | 1.2 Billion KRW | -76.27% |
| 2007 | 5.05 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 31.08 Billion KRW | -10.1% |
| 2024 Q2 | 57.83 Billion KRW | 86.07% |
| 2023 Q2 | 50.44 Billion KRW | -0.41% |
| 2023 Q4 | 34.57 Billion KRW | -28.02% |
| 2023 FY | 34.57 Billion KRW | -34.86% |
| 2023 Q1 | 50.65 Billion KRW | -4.57% |
| 2023 Q3 | 48.03 Billion KRW | -4.78% |
| 2022 Q1 | 71.97 Billion KRW | -0.37% |
| 2022 FY | 53.08 Billion KRW | -26.52% |
| 2022 Q4 | 53.08 Billion KRW | -21.17% |
| 2022 Q3 | 67.33 Billion KRW | -3.23% |
| 2022 Q2 | 69.58 Billion KRW | -3.32% |
| 2021 FY | 72.24 Billion KRW | 140.56% |
| 2021 Q2 | 48.01 Billion KRW | 58.46% |
| 2021 Q1 | 30.3 Billion KRW | 0.91% |
| 2021 Q3 | 76.66 Billion KRW | 59.66% |
| 2021 Q4 | 72.24 Billion KRW | -5.77% |
| 2020 FY | 30.02 Billion KRW | -0.94% |
| 2020 Q4 | 30.02 Billion KRW | -7.25% |
| 2020 Q2 | 30.78 Billion KRW | 1.72% |
| 2020 Q3 | 32.37 Billion KRW | 5.16% |
| 2020 Q1 | 30.26 Billion KRW | -0.16% |
| 2019 Q3 | 27.29 Billion KRW | -0.82% |
| 2019 Q2 | 27.51 Billion KRW | 47.07% |
| 2019 FY | 30.31 Billion KRW | 236.85% |
| 2019 Q4 | 30.31 Billion KRW | 11.08% |
| 2019 Q1 | 18.71 Billion KRW | 107.9% |
| 2018 Q4 | 9 Billion KRW | 200.0% |
| 2018 FY | 9 Billion KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q3 | 3 Billion KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2012 Q1 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2011 FY | - KRW | 0.0% |
| 2011 Q2 | - KRW | 0.0% |
| 2011 Q1 | - KRW | 0.0% |
| 2011 Q3 | - KRW | 0.0% |
| 2010 Q3 | 3 Billion KRW | 0.0% |
| 2010 Q1 | 3 Billion KRW | 0.0% |
| 2010 FY | - KRW | -100.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 3 Billion KRW | 0.0% |
| 2009 Q3 | 3 Billion KRW | 0.0% |
| 2009 FY | 3 Billion KRW | 150.0% |
| 2009 Q4 | 3 Billion KRW | 0.0% |
| 2009 Q1 | 2.4 Billion KRW | 100.0% |
| 2009 Q2 | 3 Billion KRW | 25.0% |
| 2008 Q3 | 1.72 Billion KRW | -66.81% |
| 2008 Q1 | 5.13 Billion KRW | 1.53% |
| 2008 FY | 1.2 Billion KRW | -76.27% |
| 2008 Q2 | 5.21 Billion KRW | 1.51% |
| 2008 Q4 | 1.2 Billion KRW | -30.62% |
| 2007 Q1 | - KRW | 0.0% |
| 2007 Q4 | 5.05 Billion KRW | 1.45% |
| 2007 FY | 5.05 Billion KRW | 0.0% |
| 2007 Q2 | - KRW | 0.0% |
| 2007 Q3 | 4.98 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -153.48% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 82.889% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -15.725% |
| HANDOK Inc. | 123.78 Billion KRW | 72.068% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -7167.532% |
| Yuhan Corporation | 60.23 Billion KRW | 42.599% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 78.656% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -33857.485% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 57.85% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -5757.059% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -471.484% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -86.664% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -174.747% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -2062.482% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -153.48% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -28789.725% |
| REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 71.426% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -8.046% |
| JW Holdings Corporation | 20.65 Billion KRW | -67.373% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -133.216% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -15.249% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -15.249% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -15690.374% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -5854.532% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 30.248% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -676.611% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -153.48% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -81.708% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 62.988% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -15.249% |
| Yuhan Corporation | 60.23 Billion KRW | 42.599% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -229.283% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 14.372% |
| Suheung Co., Ltd. | 74 Billion KRW | 53.282% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -15.249% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -729.8% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -215.391% |
| CKD Bio Corp. | 69.43 Billion KRW | 50.203% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -114.381% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -11160.075% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -15690.374% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 52.054% |
| Boryung Corporation | 151.7 Billion KRW | 77.21% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 55.97% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -471.484% |
| JW Lifescience Corporation | 168 Million KRW | -20480.214% |